Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel

Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel

Introduction: Introducing biosimilar infliximab for the treatment in rheumatology (rheumatoid arthritis and ankylosing spondylitis) and inflammatory bowel disease (Crohn's disease and ulcerative colitis) may reduce treatment costs associated with biologics. This study aimed to investigate the b...

Full description

Bibliographic Details
Main Authors:	Tim A. Kanters, Jelena Stevanovic, Isabelle Huys, Arnold G. Vulto, Steven Simoens
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2017-05-01
Series:	Frontiers in Pharmacology
Subjects:	budget impact biosimilars infliximab rheumatoid arthritis ankylosing spondylitis inflammatory bowel disease
Online Access:	http://journal.frontiersin.org/article/10.3389/fphar.2017.00322/full

Similar Items

Comparative efficacy and safety of infliximab biosimilar (BCD-055) and innovator infliximab in patients with ankylosing spondylitis (results of international, multiple-center, double-blind phase I and phase III clinical studies)
by: D. E. Karateev, et al.
Published: (2017-09-01)

Comparison between Reference Infliximab (Remicade) and its Biosimilar (Remsima) in Patients with Ankylosing Spondylitis: A Field-based Pharmacoeconomic Study
by: Hasan Raid Fadhil, et al.
Published: (2023-04-01)

COMPARATIVE EVALUATION OF THE LONG-TERM EFFICACY AND SAFETY OF THE INFLIXIMAB BIOSIMILAR BCD-055 AND REFERENCE INFLIXIMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULTS OF THE INTERNATIONAL MULTICENTER RANDOMIZED DOUBLE-BLIND PHASE III CLINICAL STUDY ASART-2
by: A. M. Lila, et al.
Published: (2018-07-01)

Patients with Ankylosing Spondylitis Can Maintain Clinical and Functional Improvement after Switching from Infliximab Reference Product to Infliximab Biosimilar (REMSIMA): 12 Months Comparative Open-Label Study
by: Abdulsatar J. Mathkhor, et al.
Published: (2022-12-01)

Comparative efficacy of infliximab and adalimumab in patients with ankylosing spondylitis
by: Tatyana Valentinovna Mezenova, et al.
Published: (2012-04-01)

ATTEMPT OF OVERCOMING SECONDARY INEFFECTIVENESS OF INFLIXIMAB IN A PATIENT WITH ANKYLOSING SPONDYLITIS USING PLASMAPHERESIS (A CASE REPORT)
by: Oksana Alekseyevna Rumyantseva, et al.
Published: (2014-02-01)

Experience with long-term infliximab therapy in patients with ankylosing spondylitis
by: Oksana Alekseevna Rumyantseva, et al.
Published: (2010-12-01)

Infliximab-induced retrobulbar optic neuritis in a patient with ankylosing spondylitis
by: Dündar, Sema, et al.
Published: (2023-12-01)

Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany
by: Evelien Moorkens, et al.
Published: (2020-10-01)

Long-term effectiveness and safety of infliximab and golimumab in ankylosing spondylitis patients from a Canadian prospective observational registry
by: Proton Rahman, et al.
Published: (2020-11-01)

The interchangeability of original tumor necrosis factor- α inhibitors and biosimilars in rheumatology: experience in replacing original infliximab with Flammagis for ankylosing spondylitis
by: Yu. V. Muravyev, et al.
Published: (2020-05-01)

Effect of HLA-B27 status and body mass index on the clinical response to infliximab in ankylosing spondylitis patients
by: Mohammed Hadi Al-Osami, et al.
Published: (2018-01-01)

Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends
by: Elif Car, et al.
Published: (2023-04-01)

The effectiveness of switching from an originator biological agent to its biosimilar, or vice versa, for ankylosing spondylitis in real clinical practice
by: K. V. Sakharova, et al.
Published: (2020-11-01)

Infusion reaction to infliximab biosimilar after transitioning from infliximab
by: Reem Kashlan, MPH, et al.
Published: (2021-02-01)

A rare case report: Myopathy related to the interaction between azathioprine and infliximab in the treatment of ulcerative colitis and ankylosing spondylitis
by: Lingyu Fu, et al.
Published: (2024-06-01)

Adherence patterns in naïve and prevalent use of infliximab and its biosimilar
by: Chibuike J. Alanaeme, et al.
Published: (2022-11-01)

Evaluation of the health care budget impact of secukinumab treatment in patients with ankylosing spondylitis
by: S. K. Zyryanov, et al.
Published: (2017-04-01)

Investigating the genetics and immunopathogenesis of ankylosing spondylitis
by: Liu, F
Published: (2024)

EFFICIENCY OF ANTI-INFLAMMATORY THERAPY IN PATIENTS WITH ANKYLOSING SPONDYLITIS ACCORDING TO THE RESULTS OF A PROSPECTIVE FOLLOW-UP STUDY
by: T. A. Raskina, et al.
Published: (2016-09-01)

Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?
by: Yujeong Kim, et al.
Published: (2020-07-01)

Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients
by: Bas J. M. Peters, et al.
Published: (2021-02-01)

Ankylosing Spondylitis
by: Nazanin Ebrahimiadib, et al.
Published: (2021-07-01)

Coincidence of Sarcoidosis With Ankylosing Spondylitis in a 48-Year-Old Woman; A Therapeutic Challenge
by: Gholam Hossein Alishiri, et al.
Published: (2020-06-01)

OSTEOPOROSIS IN PATIENTS WITH ANKYLOSING SPONDYLITIS
by: Elena Efimovna Gubar, et al.
Published: (2013-12-01)

Prevalence of fibromyalgia in patients with ankylosing spondylitis
by: Aref Hosseinian Amiri, et al.
Published: (2014-01-01)

EXPERIENCE WITH RITUXIMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS
by: Mikhail Sergeyevich Protopopov, et al.
Published: (2013-02-01)

THE THYROID GLAND STATUS IN PATIENTS WITH ANKYLOSING SPONDYLITIS DURING STANDARD THERAPY AND BIOLOGICAL THERAPY
by: G. R. Akhunova, et al.
Published: (2014-07-01)

THE THYROID GLAND STATUS IN PATIENTS WITH ANKYLOSING SPONDYLITIS DURING STANDARD THERAPY AND BIOLOGICAL THERAPY
by: G. R. Akhunova, et al.
Published: (2014-07-01)

Prospective study of patients with inflammatory back pain, clinical characteristics and treatment response in ankylosing spondylitis in two centers of rheumatology in South India
by: Subramanian Nallasivan, et al.
Published: (2022-01-01)

Coxitis in patients with ankylosing spondylitis: clinicoradio logic comparisons
by: A. G. Bochkova, et al.
Published: (2005-08-01)

COURSE OF UVEITIS IN PATIENTS WITH ANKYLOSING SPONDYLITIS
by: A. A. Godzenko, et al.
Published: (2016-09-01)

SIGNIFICANCE OF PERIPHERAL ARTHRITIS IN ANKYLOSING SPONDYLITIS
by: Sh. F. Erdes, et al.
Published: (2014-06-01)

Musculoskeletal losses in patients with ankylosing spondylitis
by: T. A. Raskina, et al.
Published: (2019-10-01)

Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative
by: Colombo GL, et al.
Published: (2018-08-01)

Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis
by: Mark C. Genovese, et al.
Published: (2020-03-01)

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
by: Fitzgerald T, et al.
Published: (2021-01-01)

Tendering and biosimilars: what role for value-added services?
by: Steven Simoens, et al.
Published: (2020-01-01)

Depression in patients with ankylosing spondylitis
by: Tianjiao Ma, et al.
Published: (2022-06-01)

HISTORY OF ANKYLOSING SPONDYLITIS: THE JOURNEY FROM DINOSAURS TO ASAS
by: Shandor F Erdes
Published: (2014-03-01)